Simeprevir (TMC435) is an oral and potent HCV NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir inhibits SARS-CoV-2 3CL activity.
In Huh7-Luc cells, antiviral activity of simeprevir (TMC435) is dose dependent, and the EC50 and EC90 values determined for simeprevir (TMC435) are 8 nM and 24 nM, respectively.
simeprevir (TMC435) inhibits NS3/4A proteases from HCV genotypes 1 to 6 with IC50s of 1/0.9/7/30/1.5/2.2/1.6 nM for 1a/1b/2b/3a/4/5/6, respectively.
体内研究
Simeprevir (TMC435) has moderate terminal elimination half-life (t1/2=1.5 h and 4.1 h for rat (3 mg/kg, p.o.), monkey (3 mg/kg, p.o.)).
Animal Model:
Sprague-Dawley (SD) rats and cynomolgus monkeys
Dosage:
3 mg/kg
Administration:
Oral administration
Result:
Time at which peak concentration (Tmax) of 1 hour and 2 hour for rat and monkey, respectively.
Concentration at 24 h after dosing (C24 h) of 0.9 and 2.3 ng/mL for rat and monkey, respectively.
AUC0-24h=1173 and1409 ng • h/mL for rat and monkey, respectively.
分子式
C38H47N5O7S2
分子量
749.94
CAS号
923604-59-5
中文名称
西咪匹韦;西米普韦
运输条件
Room temperature in continental US; may vary elsewhere.